SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Wei-Chiao Huang, Pierre-Alain Burnouf, Yu-Cheng Su, Bing-Mae Chen, Kuo-Hsiang Chuang, Chia-Wei Lee, Pei-Kuen Wei, Tian-Lu Cheng, Steve R. Roffler, Engineering Chimeric Receptors To Investigate the Size- and Rigidity-Dependent Interaction of PEGylated Nanoparticles with Cells, ACS Nano, 2016, 10, 1, 648

    CrossRef

  2. 2
    Sheema Sameen, Roberto Barbuti, Paolo Milazzo, Antonio Cerone, Marzia Del Re, Romano Danesi, Mathematical modeling of drug resistance due to KRAS mutation in colorectal cancer, Journal of Theoretical Biology, 2016, 389, 263

    CrossRef

  3. 3
    Gianluca Tomasello, Michele Ghidini, Wanda Liguigli, Margherita Ratti, Laura Toppo, Rodolfo Passalacqua, Targeted therapies in gastric cancer treatment: where we are and where we are going, Investigational New Drugs, 2016,

    CrossRef

  4. 4
    Sarah Wordsworth, James Buchanan, Adrian Towse, Genomics and Society, 2016,

    CrossRef

  5. 5
    Chongjiao Li, Yongxue Zhang, Lifei Wang, Hongyan Feng, Xiaotian Xia, Juan Ma, Hui Yuan, Bin Gao, Xiaoli Lan, A novel multivalent 99mTc-labeled EG2-C4bpα antibody for targeting the epidermal growth factor receptor in tumor xenografts, Nuclear Medicine and Biology, 2015, 42, 6, 547

    CrossRef

  6. 6
    Jifu E, Junjie Xing, Haifeng Gong, Jian He, Wei Zhang, Combine MEK inhibition with PI3K/mTOR inhibition exert inhibitory tumor growth effect on KRAS and PIK3CA mutation CRC xenografts due to reduced expression of VEGF and matrix metallopeptidase-9, Tumor Biology, 2015, 36, 2, 1091

    CrossRef

  7. 7
    Tomohiro Osaki, Cai-Xia Wang, Taro Tachibana, Masayuki Azuma, Masaya Kitamura, Takeshi Nakanishi, Generation and Characterization of Rat Monoclonal Antibodies Against Epidermal Growth Factor Receptor, Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2015, 34, 6, 418

    CrossRef

  8. 8
    Giandomenico Roviello, Karol Polom, Roberto Petrioli, Luigi Marano, Daniele Marrelli, Giovanni Paganini, Vinno Savelli, Daniele Generali, Lorenzo De Franco, Andrea Ravelli, Franco Roviello, Monoclonal antibodies-based treatment in gastric cancer: current status and future perspectives, Tumor Biology, 2015,

    CrossRef

  9. 9
    Nick Thatcher, Fred R Hirsch, Alexander V Luft, Aleksandra Szczesna, Tudor E Ciuleanu, Mircea Dediu, Rodryg Ramlau, Rinat K Galiulin, Beatrix Bálint, György Losonczy, Andrzej Kazarnowicz, Keunchil Park, Christian Schumann, Martin Reck, Henrik Depenbrock, Shivani Nanda, Anamarija Kruljac-Letunic, Raffael Kurek, Luis Paz-Ares, Mark A Socinski, Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial, The Lancet Oncology, 2015, 16, 7, 763

    CrossRef

  10. 10
    Hsin-Wei Liao, Jung-Mao Hsu, Weiya Xia, Hung-Ling Wang, Ying-Nai Wang, Wei-Chao Chang, Stefan T. Arold, Chao-Kai Chou, Pei-Hsiang Tsou, Hirohito Yamaguchi, Yueh-Fu Fang, Hong-Jen Lee, Heng-Huan Lee, Shyh-Kuan Tai, Mhu-Hwa Yang, Maria P. Morelli, Malabika Sen, John E. Ladbury, Chung-Hsuan Chen, Jennifer R. Grandis, Scott Kopetz, Mien-Chie Hung, PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response, Journal of Clinical Investigation, 2015, 125, 12, 4529

    CrossRef

  11. 11
    Xiaoyun Zhang, Ting Dong, Qiang Li, Xiaohui Liu, Lin Li, She Chen, Xiaoguang Lei, Second Generation TQ-Ligation for Cell Organelle Imaging, ACS Chemical Biology, 2015, 10, 7, 1676

    CrossRef

  12. 12
    S. Kiesgen, N. Liebers, M. Cremer, U. Arnold, T. Weber, A. Keller, C. Herold-Mende, G. Dyckhoff, D. Jager, R. E. Kontermann, M. A. E. Arndt, J. Krauss, A fusogenic dengue virus-derived peptide enhances antitumor efficacy of an antibody-ribonuclease fusion protein targeting the EGF receptor, Protein Engineering Design and Selection, 2014, 27, 10, 331

    CrossRef

  13. 13
    Renata Ferrarotto, Kathryn A Gold, Afatinib in the treatment of head and neck squamous cell carcinoma, Expert Opinion on Investigational Drugs, 2014, 23, 1, 135

    CrossRef

  14. 14
    Siu Ling Leung, Zhengbao Zha, Celine Cohn, Zhifei Dai, Xiaoyi Wu, Anti-EGFR antibody conjugated organic–inorganic hybrid lipid nanovesicles selectively target tumor cells, Colloids and Surfaces B: Biointerfaces, 2014, 121, 141

    CrossRef

  15. 15
    Margherita Ratti, Gianluca Tomasello, Emerging combination therapies to overcome resistance in EGFR-driven tumors, Anti-Cancer Drugs, 2014, 25, 2, 127

    CrossRef

  16. 16
    J. Singer, E. Jensen-Jarolim, IgE-based immunotherapy of cancer: challenges and chances, Allergy, 2014, 69, 2
  17. 17
    T. Luca, V. Barresi, G. Privitera, N. Musso, M. Caruso, D. F. Condorelli, S. Castorina, In vitro combined treatment with cetuximab and trastuzumab inhibits growth of colon cancer cells, Cell Proliferation, 2014, 47, 5
  18. 18
    Marta Herreros-Villanueva, Chih-Chieh Chen, Shyng-Shiou F. Yuan, Ta-Chih Liu, Tze-Kiong Er, KRAS mutations: Analytical considerations, Clinica Chimica Acta, 2014, 431, 211

    CrossRef

  19. 19
    Francesca Donato, Francesca Gay, Sara Bringhen, Rossella Troia, Antonio Palumbo, Monoclonal antibodies currently in Phase II and III trials for multiple myeloma, Expert Opinion on Biological Therapy, 2014, 14, 8, 1127

    CrossRef

  20. 20
    Hee Sook Choi, Kyung Tae Min, Yoon Seok Cha, Sun Pyo Hong, Multiplex detection of KRAS mutations by a matrix-assisted laser desorption/ionization-time of flight mass spectrometry assay, Clinical Biochemistry, 2014, 47, 12, 1091

    CrossRef

  21. 21
    H. Mirghani, F. Amen, F. Moreau, J. Guigay, D.M. Hartl, J. Lacau St. Guily, Oropharyngeal cancers: Relationship between epidermal growth factor receptor alterations and human papillomavirus status, European Journal of Cancer, 2014, 50, 6, 1100

    CrossRef

  22. 22
    N. Boku, K. Sugihara, Y. Kitagawa, K. Hatake, A. Gemma, N. Yamazaki, K. Muro, T. Hamaguchi, T. Yoshino, I. Yana, H. Ueno, A. Ohtsu, Panitumumab in Japanese Patients with Unresectable Colorectal Cancer: A Post-marketing Surveillance Study of 3085 Patients, Japanese Journal of Clinical Oncology, 2014, 44, 3, 214

    CrossRef

  23. 23
    Nicola Silvestris, Bruno Vincenzi, Anna Elisabetta Brunetti, Fotious Loupakis, Emanuela Dell'Aquila, Antonio Russo, Mario Scartozzi, Riccardo Giampieri, Stefano Cascinu, Vito Lorusso, Giuseppe Tonini, Alfredo Falcone, Daniele Santini, Pharmacogenomics of cetuximab in metastatic colorectal carcinoma, Pharmacogenomics, 2014, 15, 13, 1701

    CrossRef

  24. 24
    Remko van Vught, Roland J Pieters, Eefjan Breukink, SITE-SPECIFIC FUNCTIONALIZATION OF PROTEINS AND THEIR APPLICATIONS TO THERAPEUTIC ANTIBODIES, Computational and Structural Biotechnology Journal, 2014, 9, 14, 1

    CrossRef

  25. 25
    Eunsu Chung, Jiyoung Lee, Jimin Yu, Sangyeop Lee, Jin Hyun Kang, Il Yup Chung, Jaebum Choo, Use of surface-enhanced Raman scattering to quantify EGFR markers uninhibited by cetuximab antibodies, Biosensors and Bioelectronics, 2014, 60, 358

    CrossRef

  26. 26
    Sophie A. Lelièvre, Kurt B. Hodges, Pierre-Alexandre Vidi, Cancer Theranostics, 2014,

    CrossRef

  27. 27
    Kobra Omidfar, Fatemeh Sadat Amjad Zanjani, Arghavan Golbaz Hagh, Maedeh Darziani Azizi, Seyed Javad Rasouli, Susan Kashanian, Efficient growth inhibition of EGFR over-expressing tumor cells by an anti-EGFR nanobody, Molecular Biology Reports, 2013, 40, 12, 6737

    CrossRef

  28. 28
    Meizhi Wu, Lin Zhao, Lei Zhu, Zhange Chen, Huangjin Li, Expression and purification of chimeric peptide comprising EGFR B-cell epitope and measles virus fusion protein T-cell epitope in Escherichia coli, Protein Expression and Purification, 2013, 88, 1, 7

    CrossRef

  29. 29
    A. Silvestri, E. Pin, A. Huijbers, R. Pellicani, E. M. Parasido, M. Pierobon, E. Petricoin, L. Liotta, C. Belluco, Individualized therapy for metastatic colorectal cancer, Journal of Internal Medicine, 2013, 274, 1
  30. 30
    Aleksandra M. Dudek, Abhishek D. Garg, Dmitri V. Krysko, Dirk De Ruysscher, Patrizia Agostinis, Inducers of immunogenic cancer cell death, Cytokine & Growth Factor Reviews, 2013, 24, 4, 319

    CrossRef

  31. 31
    Francesco Pantano, Bruno Vincenzi, Daniele Santini, Giuseppe Tonini, Magnesium, Anti-Cancer Drugs, 2013, 24, 9, 879

    CrossRef

  32. 32
    Esther Cidon, Sara Ellis, Yasir Inam, Sola Adeleke, Sara Zarif, Tom Geldart, Molecular Targeted Agents for Gastric Cancer: A Step Forward Towards Personalized Therapy, Cancers, 2013, 5, 1, 64

    CrossRef

  33. 33
    Alessandro Allegra, Giuseppa Penna, Andrea Alonci, Sabina Russo, Bruna Greve, Vanessa Innao, Viviana Minardi, Caterina Musolino, Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma, European Journal of Haematology, 2013, 90, 6
  34. 34
    Rafael Paletta-Silva, Nathália Rocco-Machado, José Meyer-Fernandes, NADPH Oxidase Biology and the Regulation of Tyrosine Kinase Receptor Signaling and Cancer Drug Cytotoxicity, International Journal of Molecular Sciences, 2013, 14, 2, 3683

    CrossRef

  35. 35
    Satish Rajasekharan, Thiagarajan Raman, Ras and Ras mutations in cancer, Open Life Sciences, 2013, 8, 7

    CrossRef

  36. 36
    Mari Iida, Toni M Brand, Megan M Starr, Chunrong Li, Evan J Huppert, Neha Luthar, Mikkel W Pedersen, Ivan D Horak, Michael Kragh, Deric L Wheeler, Sym004, a Novel EGFR Antibody Mixture, Can Overcome Acquired Resistance to Cetuximab, Neoplasia, 2013, 15, 10, 1196

    CrossRef

  37. 37
    Alcides Chaux, Enrico Munari, Betina Katz, Rajni Sharma, Kristen Lecksell, Antonio L. Cubilla, Arthur L. Burnett, George J. Netto, The epidermal growth factor receptor is frequently overexpressed in penile squamous cell carcinomas: a tissue microarray and digital image analysis study of 112 cases, Human Pathology, 2013, 44, 12, 2690

    CrossRef

  38. 38
    Adrian Towse, Diego Ossa, David Veenstra, Josh Carlson, Louis Garrison, Understanding the Economic Value of Molecular Diagnostic Tests: Case Studies and Lessons Learned, Journal of Personalized Medicine, 2013, 3, 4, 288

    CrossRef

  39. 39
    P. Correale, C. Botta, M.G. Cusi, M.T. Del Vecchio, M.M. De Santi, G. Gori Savellini, E. Bestoso, S. Apollinari, S. Mannucci, M. Marra, A. Abbruzzese, A. Aquino, M. Turriziani, L. Bonmassar, M. Caraglia, P. Tagliaferri, Cetuximab ± chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-specific cytotoxic T-cell response in vitro, International Journal of Cancer, 2012, 130, 7
  40. 40
    Ana Markovic, Christine H Chung, Current role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinoma, Expert Review of Anticancer Therapy, 2012, 12, 9, 1149

    CrossRef

  41. 41
    Shuhui Wang, Changchun Chen, Yanchun Meng, Shi Hu, Lei Zheng, Jinjing Song, Dapeng Zhang, Bohua Li, Yajun Guo, Effective suppression of breast tumor growth by an anti-EGFR/ErbB2 bispecific antibody, Cancer Letters, 2012, 325, 2, 214

    CrossRef

  42. 42
    O. L. Polanovski, E. N. Lebedenko, S. M. Deyev, ERBB oncogene proteins as targets for monoclonal antibodies, Biochemistry (Moscow), 2012, 77, 3, 227

    CrossRef

  43. 43
    Michiel Kroesen, Dennis Lindau, Peter Hoogerbrugge, Gosse J Adema, Immunocombination therapy for high-risk neuroblastoma, Immunotherapy, 2012, 4, 2, 163

    CrossRef

  44. 44
    Arpad Zsigmond Barabas, Chad Douglas Cole, Rene Lafreniere, Donald Mackay Weir, Immunopathological events initiated and maintained by pathogenic IgG autoantibodies in an experimental autoimmune kidney disease, Autoimmunity, 2012, 45, 7, 495

    CrossRef

  45. 45
    Takashi Oshima, Munetaka Masuda, Molecular targeted agents for gastric and gastroesophageal junction cancer, Surgery Today, 2012, 42, 4, 313

    CrossRef

  46. 46
    Ailem Rabasa Capote, Jorge Ernesto González, Leyanis Rodríguez-Vera, Armando López, Belinda Sánchez Ramírez, Greta Garrido Hidalgo, Pharmacokinetics and Biodistribution Study of 7A7 Anti-Mouse Epidermal Growth Factor Receptor Monoclonal Antibody and Its Fragment in an Immunocompetent Mouse Model, ISRN Pharmacology, 2012, 2012, 1

    CrossRef

  47. 47
    Denis R. Beckford Vera, Sebastian Eigner, Katerina Eigner Henke, Ondrej Lebeda, Frantisek Melichar, Milos Beran, Preparation and preclinical evaluation of 177Lu-nimotuzumab targeting epidermal growth factor receptor overexpressing tumors, Nuclear Medicine and Biology, 2012, 39, 1, 3

    CrossRef

  48. 48
    Kobra Omidfar, Zaynab Shirvani, Single Domain Antibodies: A New Concept for Epidermal Growth Factor Receptor and EGFRvIII Targeting, DNA and Cell Biology, 2012, 31, 6, 1015

    CrossRef

  49. 49
    Mark J. Adler, Dimiter S. Dimitrov, Therapeutic Antibodies Against Cancer, Hematology/Oncology Clinics of North America, 2012, 26, 3, 447

    CrossRef

  50. 50
    J. A. J. M. van de Water, T. Bagci-Onder, A. S. Agarwal, H. Wakimoto, R. C. Roovers, Y. Zhu, R. Kasmieh, D. Bhere, P. M. P. Van Bergen en Henegouwen, K. Shah, Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects, Proceedings of the National Academy of Sciences, 2012, 109, 41, 16642

    CrossRef

  51. 51
    Jason D. Howard, Bo Lu, Christine H. Chung, Therapeutic targets in head and neck squamous cell carcinoma: Identification, evaluation, and clinical translation, Oral Oncology, 2012, 48, 1, 10

    CrossRef

  52. 52
    Jamie B. Spangler, Mandana T. Manzari, Elizabeth K. Rosalia, Tiffany F. Chen, K. Dane Wittrup, Triepitopic Antibody Fusions Inhibit Cetuximab-Resistant BRAF and KRAS Mutant Tumors via EGFR Signal Repression, Journal of Molecular Biology, 2012, 422, 4, 532

    CrossRef

  53. 53
    Erika Martinelli, Teresa Troiani, Floriana Morgillo, Fortunato Ciardiello, EGFR Inhibitors in Cancer Treatment, 2012,

    CrossRef

  54. 54
    Khaldoun Almhanna, Current Challenges in Personalized Cancer Medicine, 2012,

    CrossRef

  55. 55
    J. J. Gemmete, S. K. Mukherji, Panitumumab (Vectibix), American Journal of Neuroradiology, 2011, 32, 6, 1002

    CrossRef

  56. 56
    C Li, Personalized medicine – the promised land: are we there yet?, Clinical Genetics, 2011, 79, 5
  57. 57
    Thiruvengadam Arumugam, Craig D. Logsdon, S100P: a novel therapeutic target for cancer, Amino Acids, 2011, 41, 4, 893

    CrossRef

  58. 58
    P Mazot, A Cazes, M C Boutterin, A Figueiredo, V Raynal, V Combaret, B Hallberg, R H Palmer, O Delattre, I Janoueix-Lerosey, M Vigny, The constitutive activity of the ALK mutated at positions F1174 or R1275 impairs receptor trafficking, Oncogene, 2011, 30, 17, 2017

    CrossRef

  59. 59
    V Pavet, M M Portal, J C Moulin, R Herbrecht, H Gronemeyer, Towards novel paradigms for cancer therapy, Oncogene, 2011, 30, 1, 1

    CrossRef

  60. 60
    Boris Böll, Dennis A. Eichenauer, Bastian Von Tresckow, Denissa Peine, Michael Hallek, Andreas Engert, Kai Hübel, Activity of cetuximab as single agent in a patient with relapsed multiple myeloma, Leukemia & Lymphoma, 2010, 51, 3, 562

    CrossRef

  61. 61
    W. Bou-Assaly, S. Mukherji, Cetuximab (Erbitux), American Journal of Neuroradiology, 2010, 31, 4, 626

    CrossRef

  62. 62
    F Lordick, B Luber, S Lorenzen, S Hegewisch-Becker, G Folprecht, E Wöll, T Decker, E Endlicher, N Röthling, T Schuster, G Keller, F Fend, C Peschel, Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO), British Journal of Cancer, 2010, 102, 3, 500

    CrossRef

  63. 63
    J. B. Spangler, J. R. Neil, S. Abramovitch, Y. Yarden, F. M. White, D. A. Lauffenburger, K. D. Wittrup, Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling, Proceedings of the National Academy of Sciences, 2010, 107, 30, 13252

    CrossRef

  64. 64
    Soomin Yoon, Yong-Sung Kim, Hyunbo Shim, Junho Chung, Current perspectives on therapeutic antibodies, Biotechnology and Bioprocess Engineering, 2010, 15, 5, 709

    CrossRef

  65. 65
    Theresa L Whiteside, Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression, Expert Opinion on Biological Therapy, 2010, 10, 7, 1019

    CrossRef

  66. 66
    Byung-ung Hur, Jae-bong Yoon, Li-Kun Liu, Sang-hoon Cha, Isolation of a human anti-epidermal growth factor receptor Fab antibody, EG-19-11, with subnanomolar affinity from naïve immunoglobulin repertoires using a hierarchical antibody library system, Immunology Letters, 2010, 134, 1, 55

    CrossRef

  67. 67
    Deric L. Wheeler, Emily F. Dunn, Paul M. Harari, Understanding resistance to EGFR inhibitors—impact on future treatment strategies, Nature Reviews Clinical Oncology, 2010, 7, 9, 493

    CrossRef

  68. 68
    Matthew Zibelman, Hossein Borghaei, Anthony J. Olszanski, Antibodies in Cancer Treatment: Early Clinical Development,